Introduction
Diabetes mellitus is a condition that affects 180 million people worldwide . The total number of people with diabetes is expected to [1 ] rise to an estimated 300 million by year 2025, resulting from the population growth, ageing, obesity and sedentary lifestyle . In France, [1 ] the estimated number of individuals affected with diabetes is 2.5 million in 2007 (10 with type 1 and 90 with type 2) . The overall
prevalence of the disease was 3.95 , confirming its constant progression over time .
The prevalence of DR is supposed to be strongly related to the prevalence of diabetes. As the prevalence of diabetes is expected to rise in the future, an associated increase in the number of patients affected with DR should also be expected. Several factors have been identified as risk factors in the development of DR, including the duration of diabetes, diabetes type, poor glycemic and blood pressure control . [9 -11 ] For the past 25 years, the epidemiology of DR has been dominated by the Wisconsin Epidemiologic Study of Diabetic Retinopathy, WESDR . Other longitudinal population studies UKPDS, DCCT and EDTRS also investigated the prevalence and incidence of
[9 ] --diabetes complications . However, data from the WESDR are now outdated and reflect diabetes management used in the past. The [10 -12 ] objective of this review was to provide an update of the published literature pertaining to the epidemiology of DR and to focus on any relevant data on DR diagnosis in France.
Literature search methods
The Medline database was interrogated from 1980 to 2008. The strategy of search used the following terms: diabetic retinopathy ,
epidemiology , prevalence and incidence , limited to Human and English language . Relevant articles were original reports of
population-based studies restricted to selected Western countries (ie Europe, USA, Canada, Australia) and designed to specifically describe the prevalence and/or incidence of DR. The original Medline search generated 2460 citations, among which 58 were considered relevant.
As there are inconsistencies between epidemiological studies and differences in study methods may contribute to conflicting reports of prevalence and incidence , we restricted the search to studies using the reference method for DR diagnosis (e.g. multi-field [13 ] stereoscopic fundus photography graded by an ophthalmologist using the ETDRS classification ). In addition, we did not retain the [14 ] Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) in the present review, though a number of related articles were retrieved. There were various reasons for not selecting this study. The WESDR study was initiated in the early 1980 s. Patients included ' were grouped according to their age at diagnosis and treatment received but not according to the type of diabetes, as currently presented.
Significantly higher prevalence rates of DR were reported (up to 70 in patients treated with insulin) in contrast to more recent studies. It % is likely that improvements in the management of diabetes (better glycemic and blood pressure control) over time have led to a progressive decline in retinopathy frequency. Table 1 Denmark, Italy) using the reference examination for DR diagnosis. Patients included had known type 1 or type 2 diabetes (a few patients had newly diagnosed diabetes in , ), they were 65 years old on average (from 63 to 72) and had long-standing disease with an [15 17 ] average duration of 15 years (from 7 to 14.6).
Epidemiology of DR Western countries -

Prevalence of DR
Despite heterogeneity in patient selection criteria, country and selection period, the percentage of patients found with DR was relatively similar, ranging from 21.9 to 36.8 (weighted mean, using the number of subjects included in each study as weights, 28.7 ).
% % %
PDR accounted for about 9 of all cases of diagnosed DR (ranging from 1.6 to 4.5 , weighted mean, 2.6 ). Macular oedema
accounted for about 17 of all diagnosed DR prevalence (ranging from 2.7 to 7.6 , weighted mean 4.8 ). In summary, the % % % % prevalence rates of DR were consistent in these selected studies, suggesting that the prevalence of DR is close to 28.7 in the Western % world, i.e. in countries promoting the same strategies to manage diabetes and to control glycaemia/blood pressure levels in their populations . [23 ] In , data is presented on the Caucasian populations only, although the prevalence and risk factors of DR have been described Table 1 among multiethnic populations in the US studies. In MESA , African-American and Hispanic populations had a significantly higher [22 ] prevalence of any DR than White/Caucasian and Chinese populations. However, ethnicity was not an independent predictor of any retinopathy, suggesting that other risk factors (diabetes duration, glycemic levels) may explain the higher rates of retinopathy in African-Americans and Hispanics. Ethnic differences in DR diagnosis were also reported in the Veteran Affair Diabetes Trial cohort (VADT) . Severe retinopathy was more frequent in African Americans and Hispanics than in non-Hispanic whites/Caucasians in [24 ] VADT but, contrary to MESA, the differences could not be explained by standard risk factors. To our knowledge, the prevalence of DR according to ethnicity has not been investigated in EU countries. Only three population-based studies assessed DR longitudinally using the reference method for DR diagnosis (Melbourne VIP ; [25 ] Blue Mountains Eye Study ; AusDiab ) ( ). In all three studies, which were limited to a small number of patients, the [26 ] [27 ] Table 2 cumulative incidence of any DR was 11 (95 CI: 3.8 18.1), 22 .2 (95 CI: 14.1 32.2) and 13.9 respectively, after 5 years of
Incidence of DR
follow-up . [25 -27 ] Data of larger screening cohorts suggest that the incidence of DR is high, as well as the incidence of severe vision-threatening DR.
Primary care patients from the Liverpool Diabetic Eye Study were initially screened between 1991 and 1999 and those with no baseline DR were prospectively studied (501 type 1 and 3743 type 2 patients) , . Over a period of 5 years, the cumulative incidence of any [28 29 ] DR was 36.8 and 30.5 in type 1 and type 2 patients respectively, while sight threatening DR occurred in 3.9 in both patient groups.
% % %
Gender was not related to the incidence of any DR but longer duration of disease was associated to a greater risk of DR in both types of diabetes.
Results from long-term follow-up studies suggest that the cumulative incidence of DR decreased over the past 35 years, at least in type 1 diabetes. In the Danish Steno cohort, patients diagnosed between 1965 and 1984 were studied for up to 20 years . In the most [30 ] recently diagnosed patients, ie those referred between 1979 and 1984, a decrease of incident DR and incident MO was demonstrated,
suggesting that modern strategies to control glucose level and to lower blood pressure contributed in reducing the incidence of this diabetes complication.
DR incidence has also been evaluated in clinical trials. The event rates in clinical trial populations should theoretically be lower than those of observational cohorts, partly due to the inclusion of more compliant patients. However, in the randomized comparative DIRECT-Prevent 1 study, incident retinopathy occurred in 25 of type 1 diabetic patients treated with candesartan 31 in the placebo
group over a median period of 4.7 years . The authors suggested that DR incident rate from the placebo group probably reflects the [31 ] optimal rate achieved with the current practice.
In summary, data from different longitudinal studies suggest that the yearly incidence of any DR is approximately 2 6 . The
incidence rates are therefore only about 5 to 10 times lower than the prevalence rates, suggesting a high turn-over of patients with retinopathy, which is probably related to their short life expectancy, due to advanced age and long-standing diabetes.
Prevalence of DR France
Our search could not find any population-based studies conducted in France using a reference method to diagnose DR. In the CODIAB study the sample was mainly hospital-based, limited to a small number of patients with type 2 diabetes regularly [32 -34 ] attending hospital endocrinology consultations. DR was explored using a reference method for diagnosis (direct ophthalmoscopy, slit lamp examination, fluorescein angiography). The prevalence of any DR, proliferative DR and macular oedema was 33 , 3.3 and 5.6 % % % respectively. Advanced retinopathy (PDR, MO) increased with increased duration of diabetes and was strongly linked to other diabetes complications studied, namely peripheral neuropathy and nephropathy. Interestingly, DR prevalence was similar to prevalence rates reported in population-based studies of Western countries, although CODIAB patients were not necessarily representative of the diabetic population as they were potentially more severely affected than patients seen in private practice.
Prevalence of declared DR
Several observational studies evaluated the prevalence of known DR in France on the basis of physicians declarations ( ).
' Table 3 Retinopathy was declared in 12 of patients with type 2 diabetes in Grimaldi et al. , DR frequency being significantly increased with
increasing patient age and longer disease duration. In the cohort of patients with long-standing diabetes (mean duration, 10 15 yrs) either treated or not treated with insulin (31.1 , 12.9 and 8.6 , respectively).
ECODIA was a cross-sectional survey conducted on a representative sample of general practitioners and diabetologists/endocrinologists who collected data of 4119 ambulatory patients with type 2 diabetes . The mean duration of diabetes [37 ] was 8.9 yrs and more than a third of patients had complications linked to diabetes. In this setting, the prevalence of declared DR was 10.6 (CI 95 : 9.5 11.6 ).
In the ENTRED survey, ophthalmologic and neuropathic complications of diabetes were assessed in a representative sample, using questionnaires and patient reimbursement data from social security services . Data were analysed for 3648 subjects who had been [38 ] reimbursed for an oral antidiabetic drug and/or insulin during the fourth trimester 2001 and their 1718 corresponding physicians.
According to the patient s questionnaire, 14.5 of subjects had already had previous laser treatment and 42.6 had had a fundus The value of such observational studies is obviously limited as the patient DR status exclusively relies on the physician s declaration.
'
But for all studies combined, the frequency of known or recorded DR in French diabetic patients was around 10 and largely below the " " " " % estimated prevalence of DR resulting from epidemiological studies of 28.7 on average, suggesting that DR is under-diagnosed in patients % with diabetes, or that the prevalence of DR is much lower in France than in other Western countries, for instance because of different strategies in the screening and treatment of diabetes.
Prevalence of DR in screening programs
In 1998, a statistical analysis of the French healthcare database (French National Health Insurance CNAMTS -Caisse Nationale d'
) indicated that fewer than 40 of diabetic patients living in Metropolitan France had Assurance Maladie des Travailleurs Salaries % undergone an eye examination over the past year . One contributing factor to the low number of eye examinations was the increasing [40 ] number of diabetic patients and decreasing number of ophthalmologists to perform funduscopic examination . These observations led [41 ] to the development of more convenient methods for diagnosing or monitoring DR with at least the same sensitivity and specificity as examination by an ophthalmologist. Fundus photographies with a non mydriatic camera have been progressively used and in parallel, [42 ] ambulatory techniques have been promoted in order to enhance patient access to care . During the last 5 years, a number of different [43 ] screening programs have been conducted in France, using these alternative methods . [45 ]
Following this conclusive experience, several screening programs were implemented using non mydriatic photography. In Artois [48 ] % 7.2 ) but 6.8 had never consulted an ophthalmologist and 55 had had no eye examination over the past 2 years. Not surprisingly, % % % prevalence rates were lower than in DODIA, probably due to a selection bias. As patients are free to participate in such screening campaigns, those who volunteer are usually highly motivated and treatment-compliant. In these individuals, the rate of diabetes complications is likely to be less marked.
Finally, the largest experience of DR screening is from OPHDIAT ( a telemedical network Ophthlamology Diabetes Telemedicine) covering the Ile-de-France area . Over a 28-month period, 13777 diabetic patients with unknown retinal status were screened for DR [49 ] using non mydriatic cameras. Photographs were taken by technicians (16 screening sites located in hospitals, healthcare centres and prisons) and images were graded by trained ophthalmologists in a reading center. Diabetic retinopathy was detected in 23.4 of patients.
%
Of the patients diagnosed with DR, 0.5 had PDR and 3.4 had MO. In addition, 5.6 of patients (n 777) had undiagnosed severe DR % % % = requiring urgent referral to an ophthalmologist for laser treatment.
In summary, the evaluation of screening programs with non mydriatic fundus photography supports the view that they are effective in the identification of both early and advanced DR . More importantly, results from recent screening programs indicate ( ) that
[43 ] Table 4 10 to 20 of French diabetic patients with previous unknown retinal status have retinopathy.
In conclusion
On the basis of robust epidemiological studies conducted in the Western world over the last 20 years, we suggest that the expected prevalence of Diabetic Retinopathy is close to 28.7 in the diabetic population, while proliferative DR and macular oedema may be explained by the large proportion of patients with unknown retinal status. Although clinical guidelines recommend examination of diabetic patients for ophthalmologic complication at the time of diagnosis and on repeated annual surveillance , , , evidence suggests that [5 6 8 ] patients do not fully comply with screening and that the prevalence of DR in non compliant patients could be as high as 10 to 20 . % Alternative methods of DR screening using non mydriatic fundus photography have been validated, showing the same sensitivity and specificity for DR diagnosis as ophthalmoscopy. In addition, DR screening programs using ambulatory screening and/or combined telemedical network have been successfully conducted on a local community basis, to facilitate access to regular annual evaluations of patients with diabetes. Implementing DR screening programs that cover the entire French territory will be without a doubt, a key target for improving DR diagnosis and shortening treatment delays in patients with referable retinopathy.
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